This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2018-2019.
Company Filing History:
Years Active: 2018-2019
Title: The Innovative Contributions of Mathieu Boxus
Introduction
Mathieu Boxus is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of immunology, particularly in the development of vaccines and immunogenic compositions. With a total of 2 patents, his work is paving the way for advancements in the prevention of viral infections.
Latest Patents
Boxus's latest patents include groundbreaking innovations. The first patent focuses on immunogenic rhinovirus peptides, specifically fusion proteins that comprise a carrier protein and a Human Rhinovirus (HRV) peptide. This patent also covers immunogenic compositions that contain such fusion proteins. The second patent provides immunogenic compositions that include human picornavirus peptides derived from the structural proteins of the virus. It details constructs comprising the peptides, the peptides themselves, and their use in preventing picornavirus infection and disease, highlighting particular peptides from VP4 and VP1.
Career Highlights
Mathieu Boxus is currently associated with GlaxoSmithKline Biologicals SA, where he continues to contribute to innovative research in vaccine development. His work is instrumental in addressing public health challenges related to viral infections.
Collaborations
Throughout his career, Boxus has collaborated with esteemed colleagues such as Guy Baudoux and Brigitte Colau. These partnerships have enhanced the scope and impact of his research.
Conclusion
Mathieu Boxus exemplifies the spirit of innovation in the field of immunology. His patents and ongoing work at GlaxoSmithKline Biologicals SA are crucial in the fight against viral diseases.